Prelude Therapeutics, Inc. (PRLD)
3.21
-0.04
(-1.38%)
USD |
NASDAQ |
Nov 20, 10:35
Prelude Therapeutics Free Cash Flow : -27.95M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -27.95M |
| June 30, 2026 | -33.26M |
| March 31, 2026 | -43.78M |
| December 31, 2025 | -56.37M |
| September 30, 2025 | -100.28M |
| June 30, 2025 | -108.53M |
| March 31, 2025 | -105.85M |
| December 31, 2024 | -103.65M |
| September 30, 2024 | -107.56M |
| June 30, 2024 | -106.48M |
| March 31, 2024 | -111.71M |
| Date | Value |
|---|---|
| December 31, 2023 | -110.58M |
| September 30, 2023 | -109.19M |
| June 30, 2023 | -104.27M |
| March 31, 2023 | -94.84M |
| December 31, 2022 | -86.75M |
| September 30, 2022 | -89.43M |
| June 30, 2022 | -90.50M |
| March 31, 2022 | -91.57M |
| December 31, 2021 | -85.85M |
| September 30, 2021 | -75.03M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Q32 Bio, Inc. | -20.07M |
| Intellia Therapeutics, Inc. | -358.08M |
| Twist Bioscience Corp. | -95.96M |
| Beam Therapeutics, Inc. | -398.24M |
| Revolution Medicines, Inc. | -1.441B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -13.78M |
| Cash from Investing (Quarterly) | 9.015M |
| Cash from Financing (Quarterly) | 1.167M |
| Free Cash Flow Per Share (Quarterly) | -0.134 |
| Free Cash Flow to Equity (Quarterly) | -13.72M |
| Free Cash Flow to Firm (Quarterly) | -13.81M |
| Free Cash Flow Yield | -10.88% |